HOME >> MEDICINE >> NEWS
A threatened St. Johns wort plant could be more effective as an anti-depressant, Cornell and USDA researchers find

ver, not all St. John's wort products are the same. Previous studies have shown that the amount of hypericin in the plant - although usually labeled can vary from plant to plant, manufacturer to manufacturer, bottle to bottle and pill to pill. Thus Sirvent and Gibson are trying to determine how much of a role pre-harvest factors play in chemical differences. They are examining factors such as light, moisture, altitude and latitude; the plant parts; the plant's development stage; and the harvesting and handling practices that might affect the quality of the final product. Additionally, variations in St. John's wort products sometimes occur because manufacturers mix species of H. perforatum.

The plant typically is gathered as a weedy species in the western United States, but some is being grown commercially in the Pacific Northwest. It also is found along roadways and in fields in the eastern United States. Hypericin is concentrated in little black nodules nearly imperceptible to the untrained eye that adorn the floral edges and the plant's leaves. Curiously, St. John's wort is considered a noxious weed that can cause hypericism, or blistering and dyeing of an animal's skin when it is eaten. Its scraggly, almost frail-looking stem produces a brilliant yellow flower cluster and it grows readily in rock quarries and in marginal areas such as roadsides, where little else grows.


'"/>

Contact: Blaine Friedlander
bpf2@cornell.edu
607-255-3290
Cornell University News Service
14-Aug-2000


Page: 1 2

Related medicine news :

1. Caregivers refuse Alzheimers medications when patients quality of life threatened
2. Johns Hopkins scientists receive presidential medals
3. Robert Wood Johnson Medical School researcher receives fellowship for work in Canavan Disease
4. Rutgers announces Robert Wood Johnson Foundation Investigator Awards in Health Policy Research
5. Federal institutes and the Robert Wood Johnson Foundation create Tobacco Use Research Centers
6. Johns Hopkins To Announce AIDS Capitated Care Program
7. Success of liver transplantation may be most influenced by three risk factors
8. Tracking trends in cochlear implant complications using a federal database
9. Alcohol relapse adversely affects 10-year liver transplant survival
10. Donor age has no affect on long-term liver transplant survival
11. Age shouldnt be a factor in kidney transplantation

Post Your Comments:
(Date:11/26/2014)... Peoria, Il (PRWEB) November 27, 2014 ... is excited to announce the kick-off of its ... AlignLife encourages people to go to donate to ... will partner with local organizations to distribute the ... December 20th, participating AlignLife locations will be accepting ...
(Date:11/26/2014)... 2014 Recently, Locks-Magnetic.com, a Chinese outstanding ... of magnetic locks on the Internet. It also provides ... December. , As a leading company in the ... worldwide customers to buy high quality locks. It can ... provides locks that are not only useful but also ...
(Date:11/26/2014)... 2014 Pharmaceutical and biotech companies ... levels during manufacturing and research activities, a task ... systems play a key role. Changes in temperature ... while humidity can affect the quality of drugs ... HVAC systems helps to address these problems and ...
(Date:11/26/2014)... Alex Kramer HealthDay Reporter ... rheumatoid arthritis may be more likely to achieve remission if ... The study found that those who were heaviest had ... also lowered the odds of remission. "Medication for rheumatoid ... Dr. Susan Goodman, the study,s lead author and a rheumatologist ...
(Date:11/26/2014)... News) -- Even after they,re cleared to play following ... normal, which suggests they may not be fully recovered, ... a concussion may be symptom-free and cleared by MLB ... residual effects of concussion on the complex motor skills ... principal investigator Dr. Jeffrey Bazarian, an associate professor of ...
Breaking Medicine News(10 mins):Health News:Fresh Products Launched by Famous Company Lock-Magnetic.com 2Health News:Cleanroom Technology Market to Hit $3,761.9 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Cleanroom Technology Market to Hit $3,761.9 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Cleanroom Technology Market to Hit $3,761.9 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:Cleanroom Technology Market to Hit $3,761.9 Million by 2019 - New Research Report by MarketsandMarkets 5Health News:Weight Could Influence Rheumatoid Arthritis Relief 2Health News:Weight Could Influence Rheumatoid Arthritis Relief 3Health News:Harm From Baseball Concussions May Linger, Study Finds 2
(Date:11/26/2014)... Nov. 26, 2014  Cohen, Placitella & Roth, ... investors who purchased Nymox Pharmaceutical Corporation ("Nymox" or ... period from January 31, 2011 through November 2, ... and certain of its officers and directors publically ... of Sections 10(b) and 20(a) of the Securities ...
(Date:11/26/2014)... , Nov. 26, 2014  Avanir Pharmaceuticals, ... the U.S. Food and Drug Administration (FDA) has ... Drug Application (NDA) for AVP-825. AVP-825 is an ... powder delivered intranasally utilizing a novel Breath Powered ... Response letter, and consistent with the preliminary feedback ...
(Date:11/26/2014)... 2014  BioScrip ® , Inc. (NASDAQ: BIOS ) ... Executive Officer, will present at the Bank of America Merrill Lynch ... , Date: , , , Wednesday, December 3, 2014 , ... , , , Location: , , , Boca Raton Resort ... Inc. BioScrip, Inc. is a leading national ...
Breaking Medicine Technology:Cohen, Placitella & Roth, PC Investigating Nymox Pharmaceutical Corporation for Failing to Disclose Material Information 2Cohen, Placitella & Roth, PC Investigating Nymox Pharmaceutical Corporation for Failing to Disclose Material Information 3Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 2Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 3Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 4
Cached News: